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Abstract
Background: The development of hVISA has been associated with vancomycin clinical failures and is commonly
misidentified in clinical microbiology laboratories. Therefore, the objectives of this present study was to improve
the reliability of methodologies and criteria for identifying hVISA, evaluate the prevalence of hVISA among clinical
bloodstream isolates of S. aureus and determine if there exists a relationship between accessory gene regulator
(agr) dysfunction and the hVISA phenotype.
Methods: The presence of hVISA in 220 clinical S. aureus isolates (121 MSSA, 99 MRSA) from bloodstream
infections was examined by CLSI broth microdilution, Macro & Standard Etest. Isolates which were classified as
hVISA by Macro Etest, were additionally evaluated using a modified PAP-AUC method using a modified starting
inoculum of 1010 CFU/mL, and growth on brain heart infusion agar with 4 mg/L vancomycin (BHIV4) at 108 and
1010 CFU/mL, and agr function was assessed by delta-hemolysin production.
Results: Broth microdilution MIC50/90 of S.aureus and hVISA was 1.0/2.0 and 1.5/2.0 mg/L (p= 0.02), respectively.
Macro Etest identified 12 (5.5%) hVISA isolates; higher among MRSA (9.1%) versus MSSA (2.5%) (p = 0.03). The
mean modified PAP-AUC ratios (> 0.8) of 7 MRSA strains and 3 MSSA strains were significantly different (p = 0.001).
58% of hVISA strains were found to be agr dysfunctional when 21% of MRSA strains were agr dysfunctional. hVISA
was detected among S. aureus bloodstream isolates, which were classified as susceptible among clinical
microbiology laboratories.
Conclusions: Evaluating the correlation between Etest MICs and modified PAP-AUC ratio values will add further
improvement of discriminating hVISA, and agr dysfunction may be predictive of strains which display a greater
predilection to display the hVISA phenotype.
Background
Heteroresistant vancomycin-intermediate Staphylococcus
aureus (hVISA) has been detected in clinical S. aureus
strains throughout the world [1-3] and has been asso-
ciated with vancomycin treatment failure for S. aureus
[4]. The prevalence of hVISA has been reported ranging
from 0 to 74% [2,5]. The large variance of the hVISA
prevalence is due to the lack of a prevalence study. On
top of that, standardized methodologies and criteria to
detect hVISA in the clinical microbiology laboratory are
not established. The prevalence study with high quality
cost effective methodologies are necessary to be con-
ducted with uniformly to identify the true hVISA preva-
lence. Owing to the unstable characteristics of
vancomycin heteroresistant phenotype, establishment of
standardized methods to detect hVISA has been challen-
ging [5].
hVISA was first characterized in 1997 [6]. hVISA is
defined as isolates which are classified by the Clinical
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and Laboratory Standard Institute (CLSI) as having a
vancomycin broth microdilution minimum inhibitory
concentration (MIC) in the susceptible range where a
notable subpopulation of cells (approximately one
organism in every 105-106 or more) with MICs over the
susceptibility breakpoint [6]. A number of current meth-
odologies for detection of hVISA exist such as the Etest
Macromethod, Etest Glycopeptide Resistance Detection
(Etest GRD: Standard Etest) method and the population
analysis profile-area under the curve (PAP-AUC)
method [7]. Multiple studies demonstrated high sensitiv-
ity, high specificity, consistent and low variation between
laboratories in detecting hVISA by the Macro Etest
Method [8-10]. Although PAP-AUC is labor intensive, it
has long been considered the gold standard for hVISA
detection [2]. Furthermore, as it relates to genetic fac-
tors which can be markers for hVISA, no single resis-
tance gene has been correlated with hVISA
development [11,12]; however, it has been demonstrated
that the expression of hVISA phenotype is well asso-
ciated with dysfunction in the quorum sensing cluster of
genes, the accessory gene regulator group (agr), control-
ling colonization and virulence, as well as a number of
other regulators [13].
In this study, the objectives were to: 1) determine the
prevalence of hVISA in clinical S. aureus bloodstream
isolates utilizing Macro Etest, Standard Etest, modified
PAP-AUC method and Brain Heart Infusion Agar con-
taining vancomycin 4 mg/L (BHIAV4) method. 2) deter-
mine the relationship between hVISA, vancomycin MIC,
and agr dysfunction among clinical S. aureus blood-
stream isolates for the purpose of establishing the stan-




220 clinical S. aureus isolates obtained from the blood
of infected patients at the Buffalo Veterans Affairs
Health System of Western New York from 2003 to 2005
were analyzed. Isolates were obtained from 220 different
patients. All studies were conducted in accordance with
the Institutional review board at the University at Buf-
falo and the VA Health System. Control MSSA strain S.
aureus ATCC29213 and a standard hVISA strain Mu3
(ATCC700698) were utilized.
Antimicrobial agents, Media, and MIC Determination
Vancomycin powder (Sigma Chemical Co, St. Louis,
MO) was obtained commercially. Stock solutions were
made according to manufacturer’s directions and stored
at 4°C. Etest strips of vancomycin (AB Biodisk, Solna,
Sweden) were utilized for the initial screening of hVISA.
All susceptibility testing used Mueller-Hinton Broth
(Difco Laboratories, Detroit, MI) supplemented with cal-
cium (25 mg/L) and magnesium (12.5 mg/L). Brain-
Heart Infusion agar (Difco Laboratories, Detroit, MI)
was utilized for all analysis. Trypticase soy agar with 5%
sheep blood agar (TSA II, Becton-Dickinson Diagnos-
tics, Sparks, MD) was utilized for a bacteria growth
medium and delta-hemolysin test. CLSI Broth microdi-
lution MICs were determined for 220 clinical isolates
and a control MSSA strain S. aureus ATCC29213 and a
standard hVISA strain Mu3 in triplicate accordance
with the Clinical and Laboratory Standards Institute
(formerly the National Committee for Clinical Labora-
tory Standards) guidelines [14].
Macro and Standard Etest
The detection of hVISA among 220 isolates was com-
pleted by using the Etest Macro Method as a prelimin-
ary screen as previously described [7,15]. Overnight
growth cultures of the 220 clinical isolates and a control
MSSA strain S. aureus ATCC29213 and a standard
hVISA strain Mu3 were suspended in saline solution.
The suspensions were adjusted to 2.0 McFarland,
swabbed on the BHI plates and dried at room tempera-
ture, and Etest strips were placed on the plates. After 48
h incubation at 35°C, the intersections of the elliptical
inhibition zone and the subpopulation growth in the
inhibition zone were recorded. The criterion for Macro
Etest for detecting hVISA was the appearance of one or
more subpopulation colonies in MIC ≥4 mg/L refers to
the recent study results performed by Maor [16]. Addi-
tionally, Standard Etest was performed at a 0.5 McFar-
land using MHA that was also performed in the similar
manner and interpreted according to CLSI breakpoints.
Modified PAP-AUC
Isolates which displayed hVISA profile by the Macro
Etest Method were further analyzed using modified
PAP-AUC method according to the standard PAP-AUC
methodology as previously described [7]. Briefly, over-
night growth culture of hVISA clinical isolates and a
control isolates S. aureus ATCC29213 and a standard
hVISA strain Mu3 were suspended in saline solution.
The suspensions were adjusted to the modified starting
inoculum 1010 CFU/mL. Cultures were serially diluted
from 0 to 10-6, and 10 μL of each dilution was plated in
quadruplicate on BHI containing vancomycin in the fol-
lowing concentrations: 0.5, 1, 2, 4, 6, 8 and 16 mg/L.
Colonies were enumerated after 48 h incubation at 35°
C. Bacterial colony counts (Log10 CFU/mL) were plotted
against the vancomycin concentration (0 to 4 mg/L)
using SigmaPlot 9.0. The area under the curve (AUC)
was calculated for each isolate and divided by the AUC
value of the reference strain Mu3. The criteria for iden-
tifying hVISA were either the modified PAP-AUC ratio
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of > 0.9 or > 0.8. Additionally, modified PAP-AUC
ratios were plotted against Macro Etest MICs, which
were evaluated for the relation between two variables
using the linear regression equation and the correlation
coefficient (r).
BHIAV4
To evaluate the inoculum effect of hVISA strains
detected by the Macro Etest Method, a modified proce-
dure involving Brain Heart Infusion agar contain vanco-
mycin 4 mg/L BHIAV4 method was performed as
described previously [6]. Briefly, overnight growth cul-
ture of hVISA clinical isolates and a control isolates S.
aureus ATCC29213 and a standard hVISA strain Mu3
were suspended in saline solution. The suspensions
were adjusted to the modified inoculum of 108 and an
additional higher inoculum of 1010 CFU/mL. Each sam-
ple was plated in quadruplicate on BHI agar containing
vancomycin 4 mg/mL. Colonies were enumerated after
48 h incubation at 35°C. Growth of 1 or more colonies
indicate a positive result.
Delta-hemolysin
To evaluate the relationship between agr dysfunction
and hVISA, delta-hemolysin expression was determined
for hVISA isolates detected by Etest according to the
study previously described [13]. Briefly, overnight
growth culture of hVISA clinical isolates and S. aureus
RN4220 were suspended in saline solution. The suspen-
sions were adjusted to 0.5 McFarland standards and
were streaked vertically near RN4220 on TSA II. After
incubating plates at 35°C for 24 h, the expression of
delta-hemolysin was evaluated.
Statistical analysis
The relation between MICs (mg/L) values and modified
PAP-AUC ratios was evaluated using the linear regres-
sion analysis. The correlation coefficient (r) was calcu-
lated to display the correlation between the two
variables. The relationships between the independent
and dependent variables were analyzed using Mann-
Whitney U test and chi-square test. P-value of < 0.05
was considered statistically significant. The number of
false positive, false negative, the percentage of sensitivity
and specificity were calculated for each method.
Results
The proportion of methicillin susceptible S. aureus
(MSSA) and MRSA isolates in tested S. aureus isolates
were 55 and 45%, respectively (Table 1). The CLSI
broth microdilution MIC range for S. aureus was 0.25
to 2 mg/L, and for hVISA was 1 to 2 mg/L. The distri-
bution of MICs 0.25, 0.5, 1 and 2 mg/L measured by
the broth microdilution method were 6 (2.7%), 21
(9.5%), 159 (72.3%) and 34 (15.5%), respectively (Figure
1). MIC50 of S. aureus (n = 220), MSSA (n = 121),
MRSA (n = 99) and hVISA (determined by Macro Etest,
n = 12) were 1, 1, 1 and 1.5 mg/L, respectively. MIC50/
90 of hVISA analyzed by broth microdilution, Standard
Etest, and Macro Etest were 1.5/2, 4/4, and 6/8 mg/L,
respectively.
All tested S. aureus isolates displayed CLSI broth
microdilution MIC values in the susceptible range,
however, the distribution of MICs was significantly dif-
ferent between the total clinical S. aureus and hVISA
strains (p = 0.02). Standard Etest applying the CLSI
breakpoints identified 13 clinical S. aureus strains as
hVISA, and Macro Etest classified 1 out of those 13
hVISA strains as a vancomcyin susceptible S. aureus
(VSSA) which also displayed the low modified PAP-
AUC ratio (0.54), as shown in PAP profiles in Figure
2. The criterion for Macro Etest for detecting hVISA
was the appearance of one or more subpopulation
colonies in MIC ≥4 mg/L. hVISA prevalence was
higher in MRSA (9.1%) compared to MSSA (2.5%) (p
= 0.03) (Table 2). The Etest MIC results displayed high
reproducibility (SD < 10%).
With ten hVISA strains screened by Macro Etest and
confirmed by modified PAP-AUC with the ratio cutoff
value > 0.8, the mean modified PAP-AUC ratio (± SD)
was (0.91 ± 0.06). Additionally, the mean modified PAP-
AUC ratio (± SD) of seven hVISA isolates with MRSA
phenotype was (0.94 ± 0.04), which was higher com-
pared to the mean ratio of three hVISA isolates with
MSSA phenotype (0.85 ± 0.02) (p = 0.001). With a
higher endpoint criterion modified PAP-AUC ratio >
0.9, five hVISA strains were misclassified as susceptible.
The percentage of the sensitivity modified PAP-AUC
ratio > 0.8 and ratio > 0.9 in discriminating hVISA were
83.3% and 58.3%, respectively, when the sensitivity of
broth microdilution, Standard Etest, BHIAV4 with lower
inoculum (108 CUF/mL) and BHIAV4 with higher
inoculum (1010 CFU/mL) were 0%, 100%, 8.3% and
100%, respectively.
Macro Etest MICs were plotted against modified PAP-
AUC ratios (Figure 3). The regression line for the data
of thirteen isolates identified as hVISA by Standard
Etest is displaying the strong relationship between
Macro Etest MIC shift and modified PAP-AUC ratio (r2
= 0.78). Standard Etest also displayed the relationship
between MIC values and modified PAP-AUC ratio (r2 =
0.24). In contrast, the CLSI broth microdilusiton MIC
values did not have clear correlation with modified
PAP-AUC ratios (r2 = 0.026). According to the linear
regression equation for these two variables, Macro Etest
MICs and modified PAP-AUC ratio, the estimated mod-
ified PAP-AUC ratio at MIC 4 and 6 mg/L were 0.62
and 0.85, respectively.
Harigaya et al. BMC Infectious Diseases 2011, 11:287
http://www.biomedcentral.com/1471-2334/11/287
Page 3 of 7
The percentages of agr dysfunctional phenotype in
total tested S.aureus, MSSA, MRSA and hVISA were
15%, 10%, 21% and 58% (Table 1). The prevalence of
agr dysfunctional phenotype was significantly higher in
hVISA compared with VSSA (p = 0.02). Additionally,
the prevalence of agr dysfunctional phenotype was
higher in MRSA compared with MSSA (p = 0.02).
BHIAV4 method analysis using lower inoculum (108
CFU/mL) misclassified 11 out of 12 hVISA strains as
VSSA. On the contrary, BHIAV4 analysis with higher
inoculum (1010 CFU/mL) identified all 12 hVISA strains
as hVISA.
Discussion
Due to the heteroresistant nature of vancomycin inter-
mediate resistance, a number of clinical S. aureus may
exhibit resistant subpopulations not expressed by tradi-
tional methods of MIC detection. Therefore, it is neces-
sary to investigate a variety of methods to increase
sensitivity of hVISA detection in clinical laboratories. A
recent multicenter, multi-national comparison by Woot-
ton et. al. determined that the Macro Etest method dis-
played high sensitivity (85.9%) in detection of hVISA
which is rationale of using this method as an initial
screen for strains which display hVISA [9]. In the cur-
rent study we utilized this methodology to determine
that the hVISA phenotype was nearly four times higher
among MRSA vs. MSSA. Quantitatively, these results
were also confirmed by population analysis profiling
methods whereby MRSA displayed the higher modified
PAP-AUC ratios compared to hVISA MSSA.
This perhaps is intuitive due to vancomycin being
commonly utilized for MRSA; however, hVISA was also
detected among MSSA, which is in agreement with the
recent findings of a significant increase in vancomycin
MICs among MSSA clinical isolates by Wang [17].
These findings may suggest that the use of aggressive
vancomycin regimens, in MRSA infections are impor-
tant, so that the development hVISA phenotype which
is driven by suboptimal vancomycin therapeutic expo-
sure can be avoided. Certainly, alternative treatment
should be used for MSSA infections in lieu of vancomy-
cin treatment.
The BHIAV4 method described by Hiramatsu [6] has
been evaluated in a number of studies. One concern
with this methodology is that, the heteroresistant subpo-
pulations arise in very low frequency, which results
inability of the BHIAV4 method to detect heteroresis-
tant phenotypes when the inoculum is low. To study
the impact of inoculums on detection and mutation fre-
quency, we utilized a high inoculum of S. aureus (1010
CFU/ml) which is often observed in the severe S. aureus









MIC50/90 1/2 1/2 (p = 0.51)a 1/2 (p = 0.46)a 1.5/2 (p = 0.03)a
agr-dysfunction 15% (33/220) 10% (12/121) 21% (21/99) (p = 0.02)b 58% (7/12) (p< 0.0005)c
MIC50/90 determined by CLSI broth microdilution and the prevalence of agr-dysfunctional
a MIC distribution of total clinical S.aureus versus MIC distribution of each phenotype (Mann-Whitney U)
b Prevalence of agr dysfunction in MRSA isolates versus MSSA isolates (Chi-square test)

































































Figure 1 MIC distribution of 220 S. aureus bloodstream isolates in relation to frequency of isolates that were hVISA (A) or agr-
dysfunction (B).
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infection including infective endocarditis. As a result,
the inoculum level displayed the significant impact on
the sensitivity: the modified BHIAV4 method using the
higher inoculum 1010 CUF/mL 100% isolates additional
hVISA correctly. Furthermore, at high bacterial density,
stationary-phase growth foster biofilm formation via
quorum-sensing mechanisms involving agr in S. aureus
[13]. Coupled with the finding that proportion of agr
dysfunctional strains were nearly five times higher
among hVISA vs. VSSA, these findings may provide
additional potential mechanistic insights into the devel-
opment vancomycin resistance. Furthermore, agr dys-
functional S. aureus strains tend to display low activity
in metabolic pathway which is growth phase dependant.
Therefore, in the context of high bacterial density, it has
been hypothesized that stationary phase growth, defec-
tive autolysis profiles, biofilim production and the pro-
duction of thicker cell walls, may be facilitated by
quorum sensing mechanisms [11-13]. Finally, from a
clinical microbiology standpoint, the evaluation of delta-
Vancomycin Concentration mg/L
































Figure 2 Population analysis profiles of twelve hVISA clinical isolates, a control isolates S. aureus ATCC29213 and a standard hVISA
strain Mu3.
Table 2 Summary of the shift in MIC and PAP-AUC ratio of 13 hVISA isolates screened by Standard Etest and a control
S. aureus ATCC29213.
ID Organism BMD1 Standard Etest Macro Etest PAP-AUC Ratio hVISA2 agr-function
S183 MSSA 2 3 6 0.83 Y Positive
S189 MSSA 2 4 6 0.87 Y Negative
S200 MRSA 1 3 6 0.95 Y Negative
S211 MRSA 1 4 8 1.12 Y Positive
S213 MRSA 1 4 8 0.91 Y Positive
S214 MRSA 2 6 6 0.91 Y Positive
S223 MRSA 2 4 6 0.7 Y Positive
S226 MSSA 2 3 6 0.84 Y Negative
S231 MRSA 1 4 6 0.9 Y Negative
S239 MRSA 2 4 8 0.99 Y Negative
S262 MRSA 1 3 4 0.75 Y Positive
S285 MRSA 1 3 3 0.54 N Negative
S296 MRSA 1 3 6 0.91 Y Negative
ATCC29213 MSSA 1 2 3 0.53 N Positive
1BMD: Broth Microdilution
2Identified by Macro Etest
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hemolysin production may be of potential utility to
detect staphylococci which display an increase proclivity
to develop heterogeneous resistance.
This study had potential limitations. First, we
acknowledge the lack of geographically diverse sites for
S. aureus, as isolates were from a single institution and
limited to nosocomial bacteremia in a defined geo-
graphic area. Additional multicenter studies including
both nosocomial and community-onset bloodstream
infections are necessary to define the true prevalence
of hVISA. Second, we utilized PAP using a high initial
inoculum of 1010 CFU/mL to confirm all hVISA iso-
lates determined by the Etest Macro Method.
Although, this method may decrease specificity, our
VSSA control strain, ATCC 29213 did not display any
vancomycin intermediate populations. Third, although
we utilized delta-hemolysin expression as a surrogate
marker measure of agr function, more quantitative
measure of RNAIII expression may be necessary to
further define the relationship agr and heteroresis-
tance. Overall, the prevalence of hVISA phenotype in
220 clinical S. aureus isolates was observed to be 5.5%
in S. aureus and 9.1% in MRSA strains using the Etest
Macro Method, which was well correlated with modi-
fied PAP-AUC ratio values. agr dysfunction may add
further utility to hVISA detection in the clinical micro-
biology setting.
Conclusion
hVISA was detected among S. aureus bloodstream iso-
lates, which were classified as susceptible among clinical
microbiology laboratories. Evaluating the correlation
between Etest MICs and modified PAP-AUC ratio
values will add further improvement of discriminating
hVISA, and agr dysfunction may be predictive of strains
which display a greater predilection to display the
hVISA phenotype.
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